For the past few years, some of us have been quietly concerned about the true value of MRI scans and the accuracy of PI-RADS scores in evaluation of a patient’s risk for the presence of clinically significant prostate cancer. This is a complex issue … but data from a large, recently completed study has now validated these concerns. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: MRI, PI-RADS, risk, scan, score | 25 Comments »
Whether whole pelvic radiation therapy (WPRT) is beneficial for men newly diagnosed with Gleason grade 9/10 (Grade Group 5) is controversial. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: 10, 9, Gleason, pelvic, primary, radiation, score, whole | 1 Comment »
An obvious but previously unanswered question has been whether adding data from the results of MRI scans to the data used in the Partin tables and in the pre-surgical Kattan nomogram (also known as the Memorial-Sloan Kettering Cancer Center or MSKCC nomogram) can improve the accuracy of these two commonly used prognostic methods. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Kattan, MRI. mpMRI, MSKCC, multiparametric, nomogram, Partin, prognosis, risk, score | 3 Comments »
A commentary in Renal and Urology News this morning is entitled “Gleason 6 prostate cancer is more lethal in black men”. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: black, Gleason, mortality, non-black, risk, score | Leave a comment »
A new paper has provided us with data on the ability of genomic testing to predict adverse pathology in a man undergoing a multiparametric MRI (mpMRI) and subsequent biopsy for risk of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: assay, genomic, outcome, risk, score, test | 8 Comments »
According to a study just published in Cancer Research, a completely new technique referred to as “single cell genomics” may be able to improve the accuracy of diagnosis of prostate cancer based on biopsy tissue. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: cell, dagnosis, genomics, Gleason, grade, prognosis, score, single | 2 Comments »
A new paper just published on line in the journal PLoS One is entitled, “Association between a 17-gene genomic prostate score and a multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa)”. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: genomic, mpMRI, MRI, multi-parametric, risk, scan, score, test | Leave a comment »
We know that a family history of prostate cancer and the presence of certain genetic/genomic markers are associated with increased risk for prostate cancer in general and for some types of clinically significant prostate cancer in particular. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: counseling, family, genetic, history, PSA, risk, score, testing | 3 Comments »
A question on the minds of many prostate cancer researchers and clinicians (not to mention their patients) is if and when we may be able to replace repeat systematic prostate biopsies for patients on active surveillance (or seeking to start on active surveillance) with the significantly less invasive multiparametric MRIs (mpMRIs). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: biopsy, Gleason, grade, MRI, multiparametric, repeat, risk, scan, score | 5 Comments »
It has been hypothesized for some time that men diagnosed with a low PSA level (i.e., < 4.0 ng/ml) but a high Gleason score (of 8, 9, or 10) are at elevated risk for more advanced disease and a shorter survival time than some others. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Gleason, high, low, PSA, risk, score, survival | 4 Comments »
There have long been suggestions that men with high-risk disease who initially present with relatively low PSA levels (< 2.5 ng/ml) may be at higher than average risk for prostate cancer-specific mortality than men with higher PSA levels at diagnosis. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Diagnosis, Gleason, mortality, PSA, risk, score, Treatment | Leave a comment »
… know the Gleason score of the tissue at that positive surgical margin as well as and as opposed to just the Gleason score of the primary tumor. It makes a difference to your risk for biochemical recurrence. Your doctors need to know this information too! … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: Gleason, margin, positive, recurrence, risk, score, size, surgical | 12 Comments »
PI-RADS is an acronym and it stands for “prostate imaging — reporting and data system” but what it really is is a highly structured method for reporting what can be seen on certain types of prostate-specific magnetic resonance imaging (MRI) scan and how to interpret these data. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: classification, grade, PI-RADS, risk, score | 8 Comments »
A new study published on line in the journal Cancer has shown that (a) the cancer-specific survival benefit associated with aggressive treatment for early-stage prostate cancer is reduced with increasing co-morbidity at time of diagnosis, and (b) patients with Charlson scores ≥ 3 gain no survival benefit from aggressive treatment. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: aggressive, Charlson, Co-morbidity, early, mortality, risk, score, Treatment | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 